Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

PURPOSE: Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for advanced MCC (aMCC) demonstrate increased progression-free survival (PFS) compared with historical chemotherapy data. Howe...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Nghiem, Paul, Bhatia, Shailender, Lipson, Evan J., Sharfman, William H., Kudchadkar, Ragini R., Brohl, Andrew S., Friedlander, Phillip A., Daud, Adil, Kluger, Harriet M., Reddy, Sunil A., Boulmay, Brian C., Riker, Adam I., Burgess, Melissa A., Hanks, Brent A., Olencki, Thomas, Margolin, Kim, Lundgren, Lisa M., Soni, Abha, Ramchurren, Nirasha, Church, Candice, Park, Song Y., Shinohara, Michi M., Salim, Bob, Taube, Janis M., Bird, Steven R., Ibrahim, Nageatte, Fling, Steven P., Homet Moreno, Blanca, Sharon, Elad, Cheever, Martin A., Topalian, Suzanne L.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2019
Assuntos:
Rapid Communication
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6424137/
https://ncbi.nlm.nih.gov/pubmed/30726175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01896
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares